Dr. Chandra Teja Reddy Singareddy

Dr. Chandra Teja Reddy Singareddy is a Nuclear Medicine specialist with experience in diagnostic and therapeutic nuclear medicine. With expertise spanning advanced PET/CT imaging, gamma camera and SPECT/CT procedures, radionuclide therapies, and nuclear cardiology, Dr. Chandra Teja has actively contributed to clinical practice as well as academic research.He is currently one of the few DM Therapeutic Nuclear Medicine-trained doctors in the country. His work focuses on precision imaging and targeted radionuclide therapy, particularly in thyroid disorders, neuroendocrine tumors, and prostate cancer. He has been involved in multiple prospective studies and clinical research projects from tertiary care centers in India, contributing significantly to the advancement of nuclear medicine practice. Areas of Interest: * PET/CT with novel radiopharmaceuticals * Radionuclide therapy of thyroid, prostate and neuroendocrine tumors, Radiosynovectomy, TARE and bone pain palliation

Awarded Prof Ramdas Gold medal for best paper in Nuclear Thyroidology at SNMICON 2022, held in New Delhi. Principal Investigator of ICMR project studying the role of PET/CT in immunotherapy of breast cancer. Lead and contributing author in multiple peer-reviewed publications in reputed national and international journals. He is a member of SNMI, ANMPI, and a fellow in the Asian as well as European Nuclear Medicine Boards. Publications: Singareddy CTR, et al. Synchronous Pancreatic Solid Pseudopapillary Neoplasm Masquerading as Extralymphatic Involvement on 18F-FDG PET/CT in a Case of Hodgkin's Lymphoma. Indian J Nucl Med. 2019;34(4):309-312. Singareddy CTR, et al. Incremental value of post-high dose therapy I-131 scan over pre-therapy diagnostic I-131 scan in patients with differentiated thyroid cancer. J Clin Sci Res. 2021;9. Singareddy CTR, et al. Utility of 18F-FDG PET/CT in Management of Pancreatic and Periampullary Masses—Prospective Study from a Tertiary Care Center. Indian J Surg Oncol. 2021. Sri Charan KB, Singareddy CTR, et al. Utility of 18F-FDG PET/CT in Metabolic Characterization of Solid Renal Mass Lesion and Localization of Extra Renal Lesions. Indian J Nucl Med. 2022;37(4):329-336. Aphale R, Singareddy CTR et al. Odd Sites of Parathyroid Adenomas: 18F-fluorocholine PET/CT Pointing to the Right Place. Indian J Nucl Med. 2024;39(2):123-125. Singareddy CTR, et al. Unusual Gastric Metastasis from Invasive Ductal Carcinoma Breast Mimicking as Metachronous Primary on 18F-FDG PET/CT. Indian J Nucl Med. 2025;40(4):236-239. Singareddy CTR, et al. Radioiodine Plus Low-Dose Lenvatinib in Radioiodine-Sensitive High-Volume Metastatic Differentiated Thyroid Cancer: A Pilot Study. Clin Nucl Med. 2025 Sep 26. Singareddy CTR, et al. Seeing Beyond 68GA-DOTANOC and 18F-FDG PET/CT: 68GA-FAPI Only Uptake in a Rare Metastatic Well-differentiated Grade I Pancreatic Neuroendocrine Tumor. Clin Nucl Med. 2026 Feb 20.